Methylene blue protects primary rat retinal ganglion cells from cellular senescence

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 8, 2012, Pages 4657-4667

  Daudt III, Donald R ^a   Mueller, Brett ^a   Park, Yong H ^a   Wen, Yi ^a   Yorio, Thomas ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; HYDROGEN PEROXIDE; METHYLENE BLUE; ROTENONE; STAUROSPORINE; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; UNCOUPLING PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FEMALE; HYPOXIA; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; SENESCENCE; ANIMAL; CELL AGING; CELL CULTURE; CELL DEATH; CELL HYPOXIA; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL AGING; CELL DEATH; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; ELECTRON TRANSPORT COMPLEX IV; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; METHYLENE BLUE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; ROTENONE; STAUROSPORINE; UNCOUPLING AGENTS;

EID: 84866517519     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9734     Document Type: Article

References (55)

1. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma. 2009; 18:93-100.
2. Kisiswa L, Dervan AG, Albon J, Morgan JE, Wride MA. Retinal ganglion cell death postponed: giving apoptosis a break? Ophthalmic Res. 2010;43:61-78.
3. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004; 122:532-538.
4. Curran MP, Orman JS. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009;26: 169-184.
5. Wostyn P, De Groot V, Audenaert K, De Deyn PP. Are intracranial pressure fluctuations important in glaucoma? Med Hypotheses. 2011;77:598-600.
6. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma: is there a future role? Exp Eye Res. 2010;91:554-566.
7. Stuart EC, Rosengren RJ. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells. Life Sci. 2008;82:943-948.
8. Varma R, Peeples P, Walt JG, Bramley TJ. Disease progression and the need for neuroprotection in glaucoma management. Am J Manag Care. 2008;14:S15-S19.
9. Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care. 2008;14:S11-S14. Review.
10. Tezel G, Wax MB. Glaucoma. Chem Immunol Allergy. 2007; 92:221-227.
11. Wen Y, Li W, Poteet EC, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011;286:16504-16512.
12. Clifton J II, Leikin JB. Methylene blue. Am J Ther. 2003;10: 289-291.
13. Naylor GJ, Smith AH, Connelly P. Methylene blue in mania. Biol Psychiatry. 1988;24:941-942.
14. Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343:763-764.
15. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50:249-252.
16. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291-294.
17. Bruchey AK, Gonzalez-Lima F. Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue. Am J Pharmacol Toxicol. 2008;3:72-79.
18. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247-250.
19. Wainwright M, Crossley KB. Methylene blue: a therapeutic for all seasons? J Chemother. 2002;14:431-443.
20. Wischik C, Staff R. Challenges in the conduct of disease-modifying trails in Alzheimer's disease: practical experience from a phase 2 trail of TAU-aggregation inhibitor therapy. J Nutr Health Aging. 2009;13:367-369.
21. Riha PD, Rojas JC, Gonzalez-Lima F. Beneficial network effects of methylene blue in an amnestic model. Neuroimage. 2010; 54:2623-2634.
22. Rojas JC, Simola N, Kermath BA, Kane JR, Schallert T, Gonzalez-Lima F. Striatal neuroprotection with methylene blue. Neuroscience. 2009;163:877-889.
23. Rojas JC, John JM, Lee J, Gonzalez-Lima F. Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy. Neurotox Res. 2009;15:260-273.
24. Zhang X, Rojas JC, Gonzalez-Lima F. Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox Res. 2006;9:47-57.
25. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. 2004; 77:175-181.
26. Wrubel KM, Barrett D, Shumake J, Johnson SE, Gonzalez-Lima F. Methylene blue facilitates the extinction of fear in an animal model of susceptibility to learned helplessness. Neurobiol Learn Mem. 2007;87:209-217.
27. Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004;11:633-640.
28. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787-795.
29. Barres BA Silverstein BE, Corey DP, Chun LL. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron. 1988;1: 791-803.
30. Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage a therapeutic target of PPAR(gamma). Am J Pathol. 2011;178:2020-2031.
31. Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol. 2011; 25:429-436.
32. Kelner MJ, Alexander NM. Methylene blue directly oxidizes glutathione without the intermediate formation of hydrogen peroxide. J Biol Chem. 1985;260:15168-15171.
33. Tezel G, Wax M. Hypoxia-Inducible Factor 1 alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004;122:1348-1356.
34. Barron MJ, Griffiths P, Turnbull DM, et al. The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head. Br J Ophthalmol. 2004;88:286-290.
35. Ju WK, Crowston JG, Weinreb RN. Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci. 2007;48:2145-2151.
36. Sappington RM, Chan M, Calkins DJ. Interleukin-6 protects retinal ganglion cells from pressure-induced death. Invest Ophthalmol Vis Sci. 2006;47:2932-2942.
37. Ramdas WD, Van Koolwijk μM, Lemij HG, et al. Common genetic variants associated with open-angle glaucoma. Hum Mol Genet. 2011;20:2464-2471.
38. Mackey DA, Craig JE. Predictive DNA testing for glaucoma: reality in 2003. Ophthalmol Clin North Am. 2003;16:639-645.
39. Riha PD, Bruchey AK, Echevarria DJ, Gonzalez-Lima F. Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. 2005;511:151-158.
40. Calabrese EJ, Bachmann KA, Bailer AJ, et al. Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Applied Pharmacol. 2007;222: 122-128.
41. Bongard RD, Merker MP, Shundo R, et al. Reduction of thiazine dyes by bovine pulmonary arterial endothelial cells in culture. Am J Physiol. 1995;269:L78-L84.
42. Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 2008;22:703-712.
43. May JM, Qu ZC, Cobb CE. Reduction and uptake of methylene blue by human erythrocytes. Am J Physiol Cell Physiol. 2004; 289:C1390-C1398.
44. Zhang S, Ye J, Dong G. Neuroprotective effect of baiclein on hydrogen peroxide-mediated oxidative stress and mitochondrial dysfunction in PC12 cells. J Mol Neurosci. 2010;40:311-320.
45. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34:646-656.
46. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signaling in glaucomatous retinopathy. Eur J Ophthalmol. 2001;11:S12-S22.
47. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802-809.
48. Nguyen TL, Kim CK, Cho JH, Lee KH, Ahn JY. Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7/IGF-IR. Exp Mol Med. 2010; 42:798.
49. Chae HJ, Kang JS, Byun JO, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblast. Pharmacol Res. 2000;42:373-381.
50. Schmidt KG, Pillunat LE, Osborne NN. Ischemia and hypoxia. An attempt to explain the different rates of retinal ganglion cell death in glaucoma. Ophthalmologe. 2004;101:1071-1075.
51. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 1996;36:83-106.
52. Banasiak KJ, Xia Y, Haddad GG. Mechanisms underlying hypoxia-induced neuronal apoptosis. Prog Neurobiol. 2000; 62:215-249.
53. Miclescu A, Sharma HS, Martijn C, Wiklund L. Methylene protects the cortical blood-brain barrier against ischemia/reperfusion-induced disruption. Crit Care Med. 2010;38: 2199-2206.
54. Bardakci H, Kaplan S, Karadeniz U, et al. Methylene blue decreases ischemia-preperfusion (I/R)-induced spinal cord injury: an in vivo study in an I/R rabbit model. Eur Surg Res. 2006;38:482-488.
55. Atamna H, Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis. 2010;20:S439-S452.